<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03376789</url>
  </required_header>
  <id_info>
    <org_study_id>MYL-1501D-3004</org_study_id>
    <nct_id>NCT03376789</nct_id>
  </id_info>
  <brief_title>Mylan Insulin Glargine Study</brief_title>
  <official_title>A Randomized, Multi-center, Double-Blind, Parallel-Group Clinical Study Comparing the Efficacy and Safety of MYL-1501D Produced by Two Manufacturing Processes in Type 1 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to demonstrate similar efficacy and safety between MYL-1501D&#xD;
      products produced from two manufacturing processes (Process V and Process VI) in combination&#xD;
      with insulin lispro in patients with type 1 diabetes mellitus (T1DM).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline to Week 18</time_frame>
    <description>To test whether MYL-1501D product from Process VI once daily is non-inferior to MYL-1501D product from Process V once daily based on change in HbA1c when administered in combination with mealtime insulin lispro.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>MYL-1501D (Process V Product)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MYL-1501D (Process V Product)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MYL-1501D (Process VI Product)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MYL-1501D (Process VI Product)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MYL-1501D</intervention_name>
    <description>Process V or Process VI</description>
    <arm_group_label>MYL-1501D (Process V Product)</arm_group_label>
    <arm_group_label>MYL-1501D (Process VI Product)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written and signed informed consent needs to be provided by subjects or their legal&#xD;
             representatives before starting any protocol-specific procedures.&#xD;
&#xD;
          2. Male and female subjects between the ages of 18 to 65 years, both ages inclusive.&#xD;
&#xD;
          3. Subjects with an established diagnosis of T1DM per ADA 2017 criteria who also fulfil&#xD;
             the following criteria:&#xD;
&#xD;
               1. Initiation of insulin treatment within 6 months of T1DM diagnosis&#xD;
&#xD;
               2. Treatment with basal-bolus insulin therapy for at least 1 year before screening&#xD;
&#xD;
               3. Fasting plasma C-peptide &lt;0.3 nmol/L at screening&#xD;
&#xD;
               4. Subject has been on once daily Lantus® at stable dose (±15% variation in dose)&#xD;
                  for at least 3 months at screening&#xD;
&#xD;
          4. Body mass index (BMI) of 18.5 to 35 kg/m2 at screening (both values inclusive).&#xD;
&#xD;
          5. Stable weight, with no more than 5 kg gain or loss in the 3 months prior to screening,&#xD;
             this information will be collected by subject interview during medical history.&#xD;
&#xD;
          6. Glycosylated hemoglobin (HbA1c) ≤ 9.5% at screening.&#xD;
&#xD;
          7. Hemoglobin ≥9.0 g/dL at screening.&#xD;
&#xD;
          8. Subject has the capability of communicating appropriately with the investigator.&#xD;
&#xD;
          9. Subject is able and willing to comply with the requirements of the study protocol&#xD;
             including the 8-point self-monitored blood glucose (SMBG), completion of subject diary&#xD;
             records and following a recommended diet and exercise plan for the entire duration of&#xD;
             the study.&#xD;
&#xD;
         10. Female subjects of childbearing potential who are willing to use oral contraception or&#xD;
             two acceptable methods of contraception, (e.g., intra-uterine device plus condom,&#xD;
             spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening&#xD;
             and for the duration of the study, through study completion.&#xD;
&#xD;
               1. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation&#xD;
                  methods) and withdrawal are not acceptable methods of contraception.&#xD;
&#xD;
               2. Postmenopausal females must have had no regular menstrual bleeding for at least 1&#xD;
                  year prior to screening.&#xD;
&#xD;
               3. Female subjects who report surgical sterilization must have had the procedure at&#xD;
                  least 6 months prior to screening.&#xD;
&#xD;
               4. All female subjects of childbearing potential must have negative pregnancy test&#xD;
                  results at screening and at clinic visits, as per the SCHEDULE OF ACTIVITIES&#xD;
                  (SOA).&#xD;
&#xD;
               5. If female subjects have male partners who have undergone vasectomy, the vasectomy&#xD;
                  must have occurred more than 6 months prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of a medical condition or disease that in the investigator's&#xD;
             opinion would place the subject at an unacceptable risk from study participation.&#xD;
&#xD;
          2. History of hypersensitivity to any of the active or inactive ingredients of the&#xD;
             insulin/insulin analogue preparations used in the study, OR history of significant&#xD;
             allergic drug reactions.&#xD;
&#xD;
          3. History of use of animal insulin within the last 3 years or use of approved biosimilar&#xD;
             insulin glargine at any time prior to study entry, except for subject who previously&#xD;
             participated in MYL-1501D studies and were compliant with the study protocols.&#xD;
&#xD;
          4. History of use of a regular immunomodulator therapy in the 1 year prior to screening.&#xD;
&#xD;
          5. History of autoimmune disorders other than T1DM or insufficiently treated autoimmune&#xD;
             thyroid disorders judged clinically relevant by the investigator (recorded while&#xD;
             collecting subject history).&#xD;
&#xD;
          6. History of ≥1 episodes of diabetic ketoacidosis or emergency room visits for&#xD;
             uncontrolled diabetes leading to hospitalization within the 6 months prior to&#xD;
             screening.&#xD;
&#xD;
          7. History of clinically significant acute bacterial, viral or fungal systemic infections&#xD;
             in the last 4 weeks prior to screening (recorded while collecting subject history).&#xD;
&#xD;
          8. Any clinically significant abnormality in electrocardiogram (ECG) or safety laboratory&#xD;
             tests (LFT, RFT, hematology or any other laboratory deemed clinically relevant by the&#xD;
             investigator) conducted at screening and considered by the investigator to make the&#xD;
             subject ineligible for the study.&#xD;
&#xD;
          9. Serological evidence of human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HbSAg) or hepatitis C antibodies (HCVAb) at screening.&#xD;
&#xD;
         10. History of drug or alcohol dependence or abuse during the 1 year prior to screening.&#xD;
&#xD;
         11. Receipt of another investigational drug in the 3 months prior to screening (or as per&#xD;
             local regulations), or if the screening visit is within 5 half-lives of another&#xD;
             investigational drug received (whichever is longer), or scheduled to receive another&#xD;
             investigational drug during the current study period.&#xD;
&#xD;
         12. Subjects with the following secondary complications of diabetes:&#xD;
&#xD;
               1. Active proliferative retinopathy as confirmed by a dilated ophthalmoscopy&#xD;
                  examination / retinal photography (performed by a person legally authorized to do&#xD;
                  so) within the 6 months prior to screening.&#xD;
&#xD;
               2. Clinical nephrotic syndrome or diabetic nephropathy with a serum creatinine level&#xD;
                  &gt;1.5 times of upper limit of reference range at screening&#xD;
&#xD;
               3. History of severe form of neuropathy or cardiac autonomic neuropathy, recorded&#xD;
                  while collecting subject history. Subject's with mild or moderate forms of&#xD;
                  neuropathy will be allowed.&#xD;
&#xD;
               4. Subjects with a history of limb amputation as a complication of diabetes (at any&#xD;
                  time), or any vascular procedure during the 1 year prior to screening.&#xD;
&#xD;
               5. History of diabetic foot or diabetic ulcers in the 1 year prior to screening.&#xD;
&#xD;
         13. Any elective surgery requiring hospitalization planned during the study period.&#xD;
&#xD;
         14. Clinically significant major organ disorder at the time of screening including:&#xD;
&#xD;
               1. Uncontrolled hypertension, defined as stage 2 hypertension by Joint National&#xD;
                  Committee VII (even if therapy is ongoing, blood pressure ≥160 mm Hg systolic or&#xD;
                  ≥100 mm Hg diastolic).&#xD;
&#xD;
               2. Uncontrolled hyperlipidemia (even if therapy is ongoing, LDL &gt;160 mg/dL or&#xD;
                  triglycerides &gt;500 mg/dL).&#xD;
&#xD;
               3. Uncontrolled hyperthyroidism or hypothyroidism (subjects can be included if these&#xD;
                  conditions are controlled with thyroid hormones or anti-thyroid drugs).&#xD;
&#xD;
               4. Impaired hepatic function (alanine transaminase [ALT] or aspartate transaminase&#xD;
                  [AST] value &gt;2 times the upper limit of the reference range and/or serum&#xD;
                  bilirubin 1.5 times the upper limit of the reference range at the screening&#xD;
                  visit). Subjects with evidence of Gilberts disease may be included in the study&#xD;
                  if they have total bilirubin of &lt;3 mg/dL with indirect bilirubin contributing to&#xD;
                  &gt;80% of the total bilirubin.&#xD;
&#xD;
         15. History of a significant medical condition, such as:&#xD;
&#xD;
               1. Clinically significant cardiac disease like unstable angina, myocardial&#xD;
                  infarction, grade 3 or 4 congestive heart failure (CHF) according to New York&#xD;
                  Heart Association criteria, valvular heart disease, cardiac arrhythmia requiring&#xD;
                  treatment, and pulmonary hypertension; during the year prior to screening.&#xD;
&#xD;
               2. Stroke or transient ischemic attack (TIA) in the 6 months before screening.&#xD;
&#xD;
         16. Subjects with major depressive illness in the last 3 years (those who have&#xD;
             well-controlled depression for 3 months on a stable dose of antidepressants, with no&#xD;
             major depressive episodes in the last 3 years, can be included, even if they are on&#xD;
             medication), subjects with history of other severe psychiatric diseases (manic&#xD;
             depressive psychosis [MDP], schizophrenia), which in the opinion of the investigator&#xD;
             precludes the subject from participating in the study (recorded while collecting&#xD;
             subject history).&#xD;
&#xD;
         17. History of hematological disorders that can affect the reliability of HbA1c estimation&#xD;
             (hemoglobinopathies, hemolytic anemia, sickle cell anemia, etc.).&#xD;
&#xD;
         18. Subjects using the following in the 3 months prior to screening:&#xD;
&#xD;
               1. Insulin pump therapy&#xD;
&#xD;
               2. Any anti-diabetic drugs other than the study insulins allowed by the protocol.&#xD;
&#xD;
         19. Moderate insulin resistance, defined as requiring insulin of ≥1.5 U/IU/kg/day.&#xD;
&#xD;
         20. Subjects who have received ≥14 consecutive days of glucocorticoid therapy by oral,&#xD;
             intravenous, inhaled or other routes that produce systemic effects within the past 1&#xD;
             year, or who have received steroids by any route (except intra-nasal, intra-ocular,&#xD;
             and topical) within the 4 weeks immediately preceding screening.&#xD;
&#xD;
         21. Subjects diagnosed as having cancer (subjects with history of basal cell carcinoma,&#xD;
             carcinoma in situ or squamous cell cancer of skin, or in remission &gt;5 years, will be&#xD;
             allowed).&#xD;
&#xD;
         22. Subjects who have donated blood or plasma in the 1 month prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Valley Research</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>June 26, 2018</last_update_submitted>
  <last_update_submitted_qc>June 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MYL-1501D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>May 1, 2020</submitted>
    <returned>May 14, 2020</returned>
    <submitted>September 8, 2020</submitted>
    <returned>September 28, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

